Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Adaptive Biotechnologies Corp before investing.

In this article, we go over a few key elements for understanding Adaptive Biotechnologies Corp’s stock price such as:

• Adaptive Biotechnologies Corp’s current stock price and volume
• Why Adaptive Biotechnologies Corp’s stock price changed recently
• Upgrades and downgrades for ADPT from analysts
• ADPT’s stock price momentum as measured by its relative strength

About Adaptive Biotechnologies Corp (ADPT)

Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Want to learn more about Adaptive Biotechnologies Corp’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corp’s Stock Price as of Market Close

As of September 21, 2023, 11:15 AM, CST, Adaptive Biotechnologies Corp’s stock price was $5.17.

Adaptive Biotechnologies Corp is down 0.19% from its previous closing price of $5.18.

During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.16 and $5.49. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase.

Unfortunately, Adaptive Biotechnologies Corp’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Adaptive Biotechnologies Corp Stock Price History

Adaptive Biotechnologies Corp’s (ADPT) price is currently down 23.63% so far this month.

During the month of September, Adaptive Biotechnologies Corp’s stock price has reached a high of $6.96 and a low of $4.95.

Over the last year, Adaptive Biotechnologies Corp has hit prices as high as $10.79 and as low as $5.10. Year to date, Adaptive Biotechnologies Corp’s stock is down 81.58%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Adaptive Biotechnologies Corp Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of September 20, 2023,, no analysts have changed their rating of Adaptive Biotechnologies Corp’s stock over the last month.

Additionally, you'll want to evaluate Adaptive Biotechnologies Corp’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Adaptive Biotechnologies Corp’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Adaptive Biotechnologies Corp’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Adaptive Biotechnologies Corp (ADPT) by visiting AAII Stock Evaluator.

Relative Price Strength of Adaptive Biotechnologies Corp

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 20, 2023, Adaptive Biotechnologies Corp has a weighted four-quarter relative price strength of -14.58%, which translates to a Momentum Score of 24 and is considered to be Weak.

Want to learn more about how Adaptive Biotechnologies Corp is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Adaptive Biotechnologies Corp Stock Price: Bottom Line

As of September 21, 2023, Adaptive Biotechnologies Corp’s stock price is $5.17, which is down 0.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Adaptive Biotechnologies Corp stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.